#None #Los Angeles #Fraud Investigation #Celcuity Inc. #SBS Law

Introduction

Investors holding shares in Celcuity Inc. (NASDAQ: CELC) may be facing significant challenges as Schall, Brown & Schwartz LLP, a nationally recognized firm specializing in shareholder rights, has initiated an investigation into the company's recent actions regarding securities laws. The inquiry is prompted by concerns regarding potentially false statements or failures to disclose important information to investors.

Background on Celcuity Inc.

Celcuity is a biotechnology company focused on developing innovative treatments for cancer. Recently, the company announced that it had received FDA approval for its new breast cancer treatment, Revtorpyk (gedatolisib). While this announcement was anticipated, the company also projected that it would launch commercially in late Q3 2026, which is significantly later than what analysts had anticipated. Given the critical nature of this treatment, the delay raised immediate concerns among investors about the company’s communication and overall market strategy.

Impact of FDA Approval Delay on Share Prices

Subsequent to the announcement of the delayed commercial launch, Celcuity's stock experienced a sharp decline, plummeting 17.6% the following day. This dramatic fall in the share price suggests that investors had taken a more optimistic stance prior to the announcement and were consequently disheartened by the news. The investigation led by SBS is seeking to determine whether Celcuity misled its investors either by providing inaccurate forecasts or by failing to disclose crucial operational challenges related to the FDA approval process.

Opportunity for Affected Investors

Schall, Brown & Schwartz LLP is encouraging affected investors to take action. If you are a shareholder who has experienced losses due to the company’s questionable disclosures, you might be eligible to participate in this investigation. SBS has a track record of success in representing investors in securities class action lawsuits. The firm invites individuals to reach out for a free consultation to discuss their rights and potential next steps in the investigation process.

Why Choose Schall, Brown & Schwartz LLP?

Schall, Brown & Schwartz LLP is recognized for its expertise in securities litigation, representing individual investors and institutions across various high-profile cases. The firm is backed by experienced partners including Brian Schall, Andrew Brown, and David Schwartz, who are committed to fighting for shareholder rights. Their advocacy for transparency and accountability in corporate governance aligns with the interests of investors around the world.

Conclusion

The investigation into Celcuity Inc. by SBS Law serves as a pertinent reminder of the importance of corporate transparency and the responsibility companies have towards their investors. If you are concerned about the recent downturn in Celcuity’s stock and believe you may have been misled, it is crucial to consult a legal expert who specializes in shareholder rights. For more information or to discuss your specific situation, you are encouraged to reach out to Schall, Brown & Schwartz LLP directly. Together, investors can seek to hold corporations accountable and protect their financial interests.